Effects of Ketone Supplementation on Brain Energetics and Alcohol Consumption in Alcohol Use Disorder
University of Pennsylvania
Summary
This is a randomized, double-blind, crossover trial to evaluate the immediate effects of a nutritional ketone supplement, Kenotic compared to placebo on brain function and alcohol consumption in individuals with alcohol use disorder. Participants will complete 2 MRI scans, 2 FDG PET/CT scans, and 2 alcohol bar labs and will randomly receive Kenetik at one lab and the placebo at the next lab. During the bar labs participants will consume a dose of alcohol (based on weight), to bring their breath alcohol concentration to about 0.050%.
Description
The purpose of this research is to study how a nutritional ketone supplement, Kenetik may affect brain function and alcohol consumption in individuals with alcohol use disorder. The study will use two types of imaging to see how the brain responds to Kenetik versus a placebo beverage. The study will use magnetic resonance imaging (MRI) and fludeoxyglucose-18 (FDG) positron emission tomography (PET) scans to study the brain. MRI scans use large magnets to create a magnetic field and radio waves to produce images of the brain. The FDG PET/CT scans use small amounts of a radioactive imaging drug…
Eligibility
- Age range
- 21–65 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Age 21-65 years old 2. Able to provide written informed consent 3. Meets current DSM-5 criteria for mild to moderate (established using MINI) 4. Average weekly alcohol consumption of at least 15 standard drinks over the past month before consent (self-report) 5. Not seeking treatment for AUD (self-report) Exclusion Criteria: 1. Unwilling or unable to refrain from use of alcohol, within 24 hours of Alcohol Bar Lab, MRI and PET procedures (self-report, breathalyzer). 2. Use of psychoactive medications or medications that may affect study results (self-report, medical hi…
Interventions
- Dietary SupplementKenetik
Drink a single dose of ketone supplement 25g, three times, randomly given at 1 of 2 MRI scan visits, 1 of 2 FDG PET/CT scan visits, and 1 of 2 alcohol bar lab visits.
- Othermagnetic resonance imaging scan
Each subject will undergo 2 research MRI scan evaluations of the brain (up to 90 min.). The MRI is FDA-approved 7.0T Magentom Prisma scanner (Siemens Medical Solutions USA, Inc., Malvern, PA) with an approved radiofrequency head coil.
- Otherfludeoxyglucose-18 positron emission tomography scan
Each subject will undergo 2 FDG PET/CT scans. FDG is a positron emitting radiopharmaceutical. In addition to the radioactive FDG tracer, a low-dose CT of the chest is typically performed with the FDG PET/CT for the purpose of anatomical registration and attenuation correction of PET images. There are no separate diagnostic CT scans performed as part of this study.
- OtherAlcohol bar lab
Each subject will undergo 2 alcohol bar labs. Subjects will drink about 2 ½ standard alcohol beverages, based on their weight to reach a breath alcohol level of 0.050%.
- OtherPlacebo beverage
Location
- Center for Studies of AddictionPhiladelphia, Pennsylvania